Antibody reformatting and engineering

The design of your antibody sequence is the single most important step in your therapeutic development journey. Weak binding, off-target effects, and insufficient activity can all improve via sequence engineering.

If you want to explore novel and innovative formats (e.g. bispecifics), then further sequence engineering is necessary to introduce new mutations, build new structures, and combine new binding domains.

Expertise you can rely on for innovative antibody design

Throughout 14 years of operations, we have performed >130,000 successful production runs of different antibodies and antibody related formats, covering different species, subtypes, and isotypes, as well as a range of novel and engineered assemblies.

This depth of experience is available for all our clients to benefit from, on a royalty-free, fee-for-service basis. Whether you need to create a murine analogue of your human IgG1 therapeutic for in vivo work, or want to stitch together different variable domains with a novel backbone, evitria’s scientists are ready and willing to guide you through the design choices and share lessons learnt.  

At evitria, the process always begins with the variable domains – once we establish these sequences, our modular cloning techniques enable rapid reassembly of your construct, whether a simple process (choosing from our library of >600 different constant domains) or a more bespoke design (such as the design of bi- and multi-specific antibodies).

Fc-Silenced Antibodies by evitria

Our capabilities in antibody reformatting & engineering

01

Isotype switching


IgG
IgA
IgE
IgM

02

Fc engineering


scFv
Fab
sdAb
multispecific

03

Species switching


Silencing
Afucosylation
Half-life extension

04

Subtype switching


Human, Mouse
Rat, Rabbit
Dog, Cat
Bovine

05

Reformatting


IgG1
IgG2 (a, b, c)
IgG3
IgG4
evitria’s afucosylated antibody expression service: accessing ProBioGen’s GlymaxX® technology

Enhancing or silencing immune functions: expert antibody solutions

Frequently, our clients need to enhance immune effector functions, enhancing ADCC or CDC. Here, we have experience producing all commercially-approved ADCC enhancing mutation sets, as well as generating afucosylated antibodies with the GlymaxX® technology, an unique approach to enhancing ADCC activity.

For clients working within anti-inflammatory therapeutics, or with many bispecifics, abolishing immune effector functions may be needed. Here, we can provide silenced Fc domains, and we can guide clients through the pros and cons of working with each mutation set, including the fully silent STR technology.

As soon as you begin a project with evitria, you can count on our team’s dedication and experience to guide the way – if you are thinking about where your variable domains can take you, why not just tell us where you want to go?

Get in touch with our experts now!

Our team of experts is looking forward to talk with you about your plans, concerns and expectations regarding our expression services.

Lisa Meza San Diego contact at evitria
Richward Park Boston contact at evitria
Dr. Desmond Schofield
Chief Business Officer at evitria
Dr. Stefan Schmidt new CEO of evitria
Please enable JavaScript in your browser to complete this form.
Data protection